Journal: Frontiers in Immunology
Article Title: Development of Nipah virus mRNA vaccine for pandemic preparedness
doi: 10.3389/fimmu.2026.1843559
Figure Lengend Snippet: Production of NiV pseudovirus using the established pseudovirus system. (A) Schematic workflow of lentivirus-based and VSV-based Nipah virus pseudovirus production. (B) Confirmation of protein expression during lentivirus-based Nipah pseudovirus production. HEK293FT cells were transfected with plasmids required for lentivirus-based Nipah pseudovirus production, and protein expression was examined at 24 h and 48 h post-transfection using bright-field microscopy (left) and fluorescence microscopy (right). (C) Observation of cellular changes during VSV-based Nipah pseudovirus production. HEK293FT cells expressing NiV-F and NiV-G (left) and cells without expression of any viral proteins (right) are shown. Cells were infected with Δ G-VSV-Luc, and cellular morphology was examined 24 h post-infection. (D) Evaluation of infectivity of lentivirus-based Nipah pseudovirus. The produced lentivirus-based Nipah pseudovirus was used to infect Vero cells, and infectivity was assessed by measuring RLU using a luciferase assay at 24 h post-infection. Experiments were performed twice, and statistical analysis was conducted using an unpaired t-test (P ≥ 0.05). (E) Evaluation of infectivity of VSV-based Nipah pseudovirus. Vero cells were infected with the produced VSV-based Nipah pseudovirus or Bald VSV, and infectivity was assessed by measuring RLU values. Experiments were performed in triplicate, and statistical analysis was conducted using an unpaired t-test (*P< 0.05).
Article Snippet: HEK293FT and Vero cells (Korean Cell Line Bank, Seoul, Korea) were cultured in DMEM (Cytiva, Washington, USA) and RPMI (Cytiva, Washington, USA) containing 10% fetal bovine serum (FBS, Cytiva, Washington, USA) and 1% antibiotic–antimycotic (Gibco, Massachusetts, USA).
Techniques: Virus, Expressing, Transfection, Microscopy, Fluorescence, Infection, Produced, Luciferase